OakChart

Ensysce Biosciences Inc

ENSCHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.3601+0.0001 (0.03%)
2026-11-11 22:42 CET
Market cap
7.00 USD m
Revenue, TTM
4.50 USD m
Net income, TTM
-12.62 USD m
Free cash flow, TTM
-8.98 USD m
EPS diluted, TTM
-2.76
P/E
-
Compare

Price

ENSC against its 20, 50 and 200-day averages
2050200earnings
0.501.00249.0M498.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ENSCclose 0.3620-day 0.4450-day 0.45200-day 0.410.3652w low

83.4% under the 52-week high of 2.17 on 12 Nov 2025. 52-week low 0.23 on 14 May 2026. Last 15 sessions, 82.7% high to low

Volume 0.11× normal · the line is the 50-bar volume average

Profile

ENSC
52-week range, 7% of the way up
0.232.17

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Employees10
IPOFeb 26, 2018
Beta1.10
ATR, 14d0.05
Rel volume0.11
Short float0.48%
Insider own4.72%
Inst own5.36%

Snapshot

6 groups

Valuation

Index-
Market Cap7.00M
Enterprise Value6.19M
Income-12.62M
Sales4.50M
Book/sh-0.05
Cash/sh0.03
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPOFeb 26, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S1.56
P/B-
P/C10.30
P/FCF-
EV/EBITDA-
EV/Sales1.38
Quick Ratio0.60
Current Ratio0.60
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.76
EPS next Y-0.06
EPS next Q-0.12
EPS this Y84.92%
EPS next Y90.00%
EPS next 5Y72.81%
EPS past 3/5Y87.61% -
Sales past 3/5Y26.16% 5.21%
EPS Y/Y TTM27.41%
Sales Y/Y TTM-39.29%
EPS Q/Q74.95%
Sales Q/Q-15.10%
EarningsAug 19
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own4.72%
Insider Trans-
Inst Own5.36%
Inst Trans5.68%
ROA-295.93%
ROE-968.33%
ROIC-
Gross Margin-
Oper. Margin-281.32%
Profit Margin-280.48%
SMA20-17.51%
SMA50-19.51%
SMA200-12.42%
Trades-

Technical

Shs Outstand19.46M
Shs Float18.54M
Short Float0.48%
Short Ratio0.09
Short Interest0.09M
52W High2.17 -83.41%
52W Low0.23 56.57%
Volatility13.50% 11.24%
ATR (14)0.05
RSI (14)36.64
Beta1.10
Rel Volume0.11
Avg Volume1.01M
Volume106,536

Performance

Perf Week-2.60%
Perf Month-37.10%
Perf Quarter3.33%
Perf Half Y24.95%
Perf YTD-60.86%
Perf Year-82.35%
Perf 3Y-97.00%
Perf 5Y-100.00%
Perf 10Y-
Recom1.00
Target Price5.12
Prev Close0.36
Price0.36
Change %0.03%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 20, 2026InitiatedCCantor FitzgeraldOverweight$2+455.4%

Peers

Mkt cap
TickerCompanyMkt cap
HRTXHeron Therapeutics Inc68.36M
AZRAzora Therapeutics Inc49.99M
LPCNLipocine Inc17.61M
QUITAchieve Life Sciences Inc663.73M
CINGCingulate Inc67.47M
VTGNVistagen Therapeutics Inc8.34M
TNXPTonix Pharmaceuticals Holding Corp75.20M
KTTAPasithea Therapeutics Corp17.77M
MNOVMedicinova Inc69.40M
SILOSILO Pharma Inc2.92M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GOWER BOB GDirectorApr 23 '26Buy0.48508,614246,169516,740Aug 18 06:06 AM
GOWER BOB GDirectorAug 07 '26Buy0.49400,000198,000916,740Aug 18 06:06 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai (ACCESSWIRE)
  • Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA (ACCESSWIRE)
  • Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation (ACCESSWIRE) -6.19%
  • Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs (ACCESSWIRE)
  • Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation (ACCESSWIRE) +14.09%
  • Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study (ACCESSWIRE)
  • Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium (ACCESSWIRE)
  • Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights (ACCESSWIRE) -12.59% +14.75%
  • Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing (InvestorsHub) +44.83%
  • Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing (ACCESSWIRE)
  • Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development (InvestorsHub) +6.17%
  • Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant (ACCESSWIRE)
  • Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study (ACCESSWIRE) +6.33%
  • Ensysce Biosciences Reports First Quarter 2026 Financial Results (ACCESSWIRE) +13.17%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-19-0.200-0.200-1.201.201
2026Q12026-05-18-0.520-0.730-1.001.901
2025Q42026-03-26-0.750-1.260-0.7501.900.501
2025Q32025-11-17-1.290--1.2920.49--
2025Q12025-05-13-1.390-3.015-1.3891.310.002
2024Q42025-03-17-2.900-2.735-2.6291.300.252
2024Q32024-11-141.0501.0501.0043.413.401
2024Q22024-08-14-3.300-5.850-3.3480.200.302
2024Q12024-05-14-8.250-13.500-8.2100.310.402
2023Q42024-03-15-16.950-13.050-16.7080.510.402
2023Q32023-11-09-13.050-15.851-13.0740.420.593
2023Q22023-08-11-14.700-27.800-14.7490.500.763
2023Q12023-05-15-31.200-76.151-31.2490.800.953
2022Q42023-03-31-22.800-36.101-273.61.401.543
2022Q32022-11-22-76.950-2.400-923.690.301.002
2022Q22022-11-14-3.600-2.550-847.261.001.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-266.4-111.6-5,3362.602.70
2022FY-174.3-1,803-2,0912.512.64
2023FY-70.350-44.025-70.4002.222.11
2024FY-11.450-8.335-11.4485.214.15
2025FY-3.980-4.730-5.103.70
2026FY--0.600--4.50
2027FY--0.060--2.75
2028FY--0.080--0.00
2029FY--0.080--0.00
2030FY--0.080--14.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-272001.201.201.20
2026Q3S2026-10-192011.201.201.20
2026Q3S2026-08-191011.201.201.20
2026Q3S2026-08-131011.201.201.20
2026Q3S2026-08-051015.305.305.30
2026Q3S2026-07-131105.405.405.40
2026Q3S2026-05-181001.901.901.90
2026Q3S2026-03-301001.901.901.90
2026Q3E2026-10-27200-0.12-0.19-0.05
2026Q3E2026-10-19201-0.12-0.19-0.05
2026Q3E2026-08-19101-0.19-0.19-0.19
2026Q3E2026-08-13101-0.19-0.19-0.19
2026Q3E2026-08-051010.040.040.04
2026Q3E2026-07-131100.090.090.09

Estimate history

EPS, annual-4.46430655.87212.384-5335.74-2091.244-70.4-11.448-3.979-2.7593
Period201720182019202020212022202320242025TTM
EPS, quarterly-3.3481.004-2.629-1.389-0.787-1.292-0.75-0.52-0.197
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0003.9313.5312.5232.2315.215.0674.5
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1823.4191.3041.321.3710.4931.8820.9611.164
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0070.0070.0070.0040.0070.0360.211.3564.57516.228
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.5430.9251.3561.6452.3933.1814.5759.27816.228
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.505.075.212.232.523.533.930.000.00
Cost of Goods Sold Incl. D&A-----0.000.000.000.00
Gross Profit-----3.533.930.000.00
Selling, General and Administrative Excl. Other17.1415.3011.9412.9526.7523.405.543.331.56
Research and Development12.3910.387.227.5919.844.694.39--
Other Operating Expense0.000.000.000.000.000.000.000.00-0.60
Operating Income-12.66-10.24-6.73-10.72-24.22-19.87-1.61-3.33-0.96
Interest Expense0.020.021.290.351.253.221.00-0.00
Unusual Expense-0.00-0.01-0.02-0.43-1.185.62-2.450.00-0.01
Net Income Before Taxes-12.62-10.18-7.99-10.63-24.21-29.15-0.160.922.68
Income Taxes0.000.000.000.000.000.000.000.560.55
Consolidated Net Income-12.62-10.18-7.99-10.63-24.21-29.15-0.160.37-1.34
Net Income From Continuing Operations-12.62-10.18-7.99-10.61-24.17-29.080.060.37-1.34
Net Income-12.62-10.18-7.99-10.63-25.09-29.890.060.37-1.34
EPS (Recurring)-0.97-3.98-11.46-72.40-2,159.84-4,632.99-361.3155.86-194.48
EPS (Basic, Before Extraordinaries)-2.76-3.98-11.45-70.40-2,091.24-5,335.7412.9655.87306.00
EPS (Diluted)-2.76-3.98-11.45-70.40-2,091.24-5,335.7412.3855.87306.00
EBITDA-12.64-10.23-6.73-10.72-24.22-19.87-1.61-3.33-0.96
Non-Operating Income (Expense)0.050.070.020.020.09-0.440.004.253.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.00-3.46
Stock Option Compensation Expense1.190.810.110.881.070.120.18--
Price To Earnings Ratio------18.49852.00115.64
Price To Sales Ratio0.840.461.091.080.6426.8452.21--
Gross Margin-----100.0099.99--
Operating Margin-281.32-202.12-129.18-480.52-959.91-562.71-41.04--
Net Margin-280.48-200.84-153.30-476.39-994.12-846.371.44--
Shares Outstanding16.234.571.360.210.040.010.000.010.01
Market Capitalization7.007.0010.623.041.66115.8277.40248.79245.50

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.160.961.880.491.371.321.303.42
Cost of Goods Sold Incl. D&A0.010.01------
Gross Profit1.160.95------
Selling, General and Administrative Excl. Other3.734.524.664.233.123.294.882.77
Research and Development2.473.353.612.951.921.893.801.69
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.58-3.56-2.78-3.74-1.75-1.97-3.580.64
Interest Expense0.000.000.010.010.000.000.010.00
Unusual Expense0.000.00-0.00-0.000.00-0.010.01-0.01
Net Income Before Taxes-2.57-3.56-2.77-3.73-1.73-1.95-3.560.66
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.57-3.56-2.77-3.73-1.73-1.95-3.560.66
Net Income From Continuing Operations-2.57-3.56-2.77-3.73-1.73-1.95-3.560.66
Net Income-2.57-3.56-2.77-3.73-1.73-1.95-3.560.66
EPS (Recurring)-0.20-0.52-0.75-1.29-0.79-1.39-2.631.00
EPS (Basic, Before Extraordinaries)-0.20-0.52-0.75-1.29-0.79-1.39-2.631.00
EPS (Diluted)-0.20-0.52-0.75-1.29-0.79-1.39-2.631.00
EBITDA-2.57-3.56-2.78-3.74-1.75-1.97-3.580.64
Non-Operating Income (Expense)0.010.010.020.020.020.020.030.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.650.010.440.100.210.020.030.02
Price To Sales Ratio0.840.780.671.520.660.582.120.54
Gross Margin99.4499.32------
Operating Margin-221.28-370.68-147.79-758.68-127.64-149.08-274.3418.86
Net Margin-220.79-370.07-147.03-756.26-126.39-147.42-273.4219.36
Shares Outstanding16.239.284.573.182.391.641.360.92
Market Capitalization7.001.963.347.045.293.6010.623.33

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.313.501.123.1512.260.191.061.662.09
Short Term Receivables0.420.120.100.280.440.000.000.170.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.511.721.071.872.960.150.140.090.22
Total Current Assets7.245.342.295.3015.660.351.201.922.31
Net Property, Plant & Equipment0.120.000.000.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00195.31202.92200.12
Intangible Assets0.00----0.000.000.000.00
Other Assets0.090.250.420.590.750.000.000.000.00
Total Assets7.455.602.715.8916.420.35196.51204.83202.43
Short Term Debt Incl. Current Port. of LT Debt0.280.290.854.2812.613.480.000.000.00
Accounts Payable3.271.361.942.940.301.720.000.000.00
Income Tax Payable-------0.000.00
Other Current Liabilities1.020.560.542.243.571.802.770.440.15
Total Current Liabilities4.572.213.339.4616.487.012.770.440.16
Long Term Debt0.000.000.000.144.440.000.570.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-------0.00-
Other Liabilities0.000.010.030.313.650.007.007.007.00
Total Liabilities4.572.223.369.9124.587.0110.347.447.16
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00192.39190.27
Common Equity3.213.71-0.32-3.71-7.88-6.44186.175.005.00
Total Shareholders Equity3.213.71-0.32-3.71-7.88-6.44186.17197.39195.27
Accumulated Minority Interest-0.33-0.33-0.33-0.32-0.28-0.220.000.000.00
Total Equity2.883.38-0.65-4.03-8.16-6.66186.17197.39195.27
Total Liabilities & Stockholders Equity7.455.602.715.8916.420.35196.51204.83202.43
Book Value Per Share0.702.74-1.54-104.24-1,150.89-1,470.4428,070.93720.00699.03
Tangible Book Value Per Share0.702.74-1.54-104.24-1,150.89-1,470.4428,070.93720.00699.03
Full-Time Employees10991212----
Price to Book Ratio-7.471.092.04-0.27-14.70-64.121.3449.1049.05
Return on Assets-155.95-192.33-247.01-216.77-198.710.060.18-0.66-
Return on Equity-294.00-471.82---0.060.19-0.68-
Return on Invested Capital-316.63-215.37----0.20-0.68-0.02
Quick Ratio1.592.420.690.560.950.050.434.3814.77
Current Ratio1.592.420.690.560.950.050.434.3814.77

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-12.62-10.18-7.99-10.63-24.21-29.15-0.160.372.12
Depreciation-0.01--0.000.000.00--
Other Funds (Non Cash)1.200.851.340.790.7821.86-1.658.17-3.64
Funds from Operations-11.40-9.32-6.65-9.83-23.43-7.29-1.818.53-1.51
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.551.52-0.85-0.955.54-0.950.572.460.27
Income Taxes Payable-------0.00-0.00
Cash from Operating Activities-8.86-7.81-7.50-10.78-17.89-8.24-1.2510.99-1.24
Capital Expenditures-0.12-0.120.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00-0.570.00
Purchase of Investments0.000.000.000.000.000.000.00-0.570.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.84
Cash from Investing Activities-0.12-0.120.000.000.000.000.00-0.570.84
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.059.8512.219.053.246.890.00-11.59-0.03
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-11.580.00
Sale of Common Pref Stock8.059.8512.219.053.246.890.00-0.01-0.03
Proceedsfrom Stock Options8.447.654.109.053.246.630.00-0.01-0.03
Issuance or Reduction of Debt, Net0.000.00-0.490.616.1313.911.100.570.00
Change in Long Term Debt0.000.000.000.006.1314.031.000.570.00
Issuance of Long Term Debt0.000.000.000.007.5314.031.000.570.00
Reduction of Long Term Debt0.000.000.000.00-1.410.000.000.000.00
Net Financing Active Other Cash Flow-0.61-1.11-1.84-0.90-0.60-0.492E-050.000.00
Other Financing Activities Uses-0.61-1.11-1.84-0.90-0.60-0.490.000.000.00
Cash from Financing Activities7.448.749.888.768.7720.311.10-11.03-0.03
Net Change in Cash-1.530.812.38-2.02-9.1212.07-0.15-0.60-0.43
Free Cash Flow-8.98-7.93-7.50-10.78-17.89-8.24-1.2510.99-1.24
Preferred Dividends (Cash Flow)-0.00----0.000.000.00
Price to Free Cash Flow------0.7122.35-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.680.754.311.672.213.05
Short Term Receivables0.420.000.420.001.200.02
Inventories0.000.000.000.000.000.00
Other Current Assets1.361.262.511.251.871.33
Total Current Assets2.452.017.242.935.284.40
Net Property, Plant & Equipment0.110.120.120.120.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.00-0.000.000.00-
Other Assets0.390.040.090.130.290.21
Total Assets2.962.177.453.185.574.61
Short Term Debt Incl. Current Port. of LT Debt0.200.220.280.360.400.24
Accounts Payable1.981.613.270.461.040.62
Other Current Liabilities1.891.011.021.481.070.91
Total Current Liabilities4.072.844.572.302.511.76
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.003E-050.000.13
Total Liabilities4.072.844.572.302.511.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-0.78-0.343.211.203.393.05
Total Shareholders Equity-0.78-0.343.211.203.393.05
Accumulated Minority Interest-0.33-0.33-0.33-0.33-0.33-0.33
Total Equity-1.11-0.672.880.873.062.72
Total Liabilities & Stockholders Equity2.962.177.453.185.574.61
Book Value Per Share-0.05-0.040.700.381.421.85
Tangible Book Value Per Share-0.05-0.040.700.381.421.85
Full-Time Employees--10---
Price to Book Ratio-7.470.772.431.671.200.94
Return on Assets-295.93-347.70-155.95-174.66-157.26-140.74
Return on Equity-968.33-870.19-294.00-270.54-253.29-200.53
Return on Invested Capital---86.12-309.89-51.15-63.81
Quick Ratio0.600.711.591.272.102.50
Current Ratio0.600.711.591.272.102.50

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.57-3.56-2.77-3.73-1.73-1.95
Depreciation0.010.01----
Other Funds (Non Cash)0.650.010.440.100.250.06
Funds from Operations-1.92-3.54-2.32-3.63-1.48-1.89
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.050.040.791.76-1.220.18
Cash from Operating Activities-1.96-3.50-1.53-1.87-2.71-1.71
Capital Expenditures0.000.000.00-0.120.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.120.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.890.004.661.502.241.45
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.890.004.661.502.241.45
Proceedsfrom Stock Options1.890.006.550.001E-061.10
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.06-0.50-0.05-0.38-0.19
Other Financing Activities Uses0.00-0.06-0.50-0.05-0.38-0.19
Cash from Financing Activities1.89-0.064.161.451.871.26
Net Change in Cash-0.07-3.562.64-0.54-0.84-0.45
Free Cash Flow-1.96-3.50-1.53-1.99-2.71-1.71

Revenue breakdown

MPAR2024: 3.09M 2025: 5.07M
TAAP/OUD2024: 2.12M
United States2024: 5.21M 2025: 5.07M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.48%0.1M18.5M13.76M
2026-10-151.64%0.3M18.5M13.76M
2026-09-305.83%1.1M18.5M14.20M
2026-09-156.50%1.2M18.5M14.53M
2026-08-317.70%1.4M18.5M14.44M
2026-08-146.23%1.1M18.3M14.59M
2026-07-311.25%0.2M15.4M2.52M
2026-07-152.63%0.4M15.4M2.56M
2026-06-301.19%0.2M15.4M2.20M
2026-06-152.37%0.4M15.4M2.19M
2026-05-290.34%0.1M14.7M2.33M
2026-05-155.55%0.8M14.7M7.35M
2026-04-300.57%0.1M9.3M6.07M
2026-04-150.70%0.1M9.3M6.14M
2026-03-312.11%0.2M9.3M6.11M
2026-03-133.67%0.1M3.6M5.94M
2026-02-279.02%0.3M3.6M5.61M
2026-02-134.68%0.2M3.6M400.99K
2026-01-305.56%0.2M3.6M208.80K
2026-01-155.67%0.2M3.6M205.09K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-10-29SEC
2026-10-30PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-30SEC
2026-10-23S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-168-K/A2026-08-05SEC
2026-09-298-KCurrent report2026-09-25SEC
2026-08-258-KCurrent report2026-08-25SEC
2026-08-248-KCurrent report2026-08-24SEC
2026-08-20DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-18SCHEDULE 13D/ASEC
2026-08-184Statement of changes in beneficial ownership of securities2026-04-23SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-103Initial statement of beneficial ownership of securities2026-08-05SEC
2026-08-068-K/A2026-08-05SEC
2026-08-068-KCurrent report2026-08-05SEC
2026-07-158-KCurrent report2026-07-15SEC
2026-06-26EFFECTEffectiveness filing by commission orderSEC
2026-06-04S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-228-KCurrent report2026-05-22SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-04-30S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-15EFFECTEffectiveness filing by commission orderSEC
2026-04-14CORRESPSEC
2026-04-13UPLOADUpload SubmissionSEC
2026-04-09S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-04-088-KCurrent report2026-04-07SEC
2026-04-038-KCurrent report2026-04-03SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-308-KCurrent report2026-03-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08198.00K100
2026-070000
2026-060000
2026-050000
2026-04246.17K100
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC1.36%
ADAGE CAPITAL PARTNERS GP, L.L.C.0.97%
StoneX Group Inc.0.71%
Virtu Financial LLC0.62%
PERCEPTIVE ADVISORS LLC0.56%
CITADEL ADVISORS LLC0.56%
XTX Topco Ltd0.50%
HRT FINANCIAL LP0.35%
GEODE CAPITAL MANAGEMENT, LLC0.32%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.22%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.31%
VANGUARD EXTENDED MARKET INDEX FUND0.08%

OakChart. ENSC. Cached 15 minutes.